Common TitleGS-366-1216
Official Title A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Phase Phase IIIB
ClinicalTrials.gov NCT02345252
Treatments
Tenofovir alafenamide-Emtricitabine![Tenofovir alafenamide-Emtricitabine Descovy](https://cdn.hiv.uw.edu/css/images/drugs/32.png)
, ![Tenofovir alafenamide-Emtricitabine Descovy](https://cdn.hiv.uw.edu/css/images/drugs/32.png)
Tenofovir alafenamide-Emtricitabine
Tradename:DescovyOther Names:TAF-FTCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Rilpivirine-Tenofovir alafenamide-Emtricitabine![Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey](https://cdn.hiv.uw.edu/css/images/drugs/45.png)
![Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey](https://cdn.hiv.uw.edu/css/images/drugs/45.png)
Rilpivirine-Tenofovir alafenamide-Emtricitabine
Tradename:OdefseyOther Names:RPV-TAF-FTCClass:Single-Tablet RegimensFunding
IndustryGilead Sciences